← 返回前沿论文

CAR-T 细胞来源的细胞外囊泡:一种潜在的癌症治疗手段

英文原题:Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer.

查看英文原题

Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer.

PubMed 2021/10/01(内容时间) Hum Gene Ther Q1 · IF 4.6(JCR 2025)

研究概要

CAR-T EVs提供了一种新型强效免疫治疗方法,可能对实体瘤有效。

中文摘要

嵌合抗原受体(CAR)-T 细胞是经过基因工程改造的 T 细胞,靶向肿瘤相关抗原。来源于 CAR-T 细胞的细胞外囊泡(EVs)(CAR-T EVs)可能保留 CAR-T 活性,并克服导致实体瘤患者 CAR-T 细胞治疗失败的主要障碍之一。本研究旨在比较 CAR-T EVs 与其亲本细胞,并探讨其细胞穿透能力和细胞毒性活性。抗 HER-2 CAR 被特异性靶细胞刺激。从细胞培养基中分离 EVs,并对其内容物和功能进行表征。我们发现 CAR-T EVs 含有小 EVs 和大 EVs 的混合物。与亲本 CAR-T 细胞相比,受刺激的抗 HER-2 + CAR-T EVs 表达的细胞因子水平较低(如干扰素 gamma)。与未刺激细胞来源的 EVs 相比,CAR-T EVs 中颗粒酶 B 水平更高(20)(p < 0.001)。抗 HER-2 + CAR-T EVs 特异性结合并穿透表达 HER-2 的靶细胞。通过 caspase-3/7 活性测得的细胞毒性效应在 CAR-T 细胞及其来源 EVs 中相似。然而,CAR-T 细胞在最初 24 h 内诱导大量凋亡,而 CAR-T EVs 需要 60 - 90 h。总之,CAR-T EVs 提供了一种新型强效免疫治疗方法,可能对实体瘤有效。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells, directed against a tumor-associated antigen. Extracellular vesicles (EVs) derived from CAR-T cells (CAR-T EVs) may preserve CAR-T activity and overcome one of the major obstacles responsible for CAR-T cell failure in patients with solid tumors. This study aimed to compare CAR-T EVs with their parental cells and explore their cell penetration and cytotoxic activity. Anti-HER-2 CARs were stimulated with specific target cells. EVs were isolated from the cell media and characterized for their content and functions. We found that CAR-T EVs contained a mixture of small and large EVs. Stimulated anti-HER-2 + CAR-T EVs expressed lower cytokine levels compared with their parental CAR-T cells (such as interferon gamma). Higher levels of granzyme B were found in CAR-T EVs ( 20 ) compared with EVs from unstimulated cells ( p < 0.001). Anti-HER-2 + CAR-T EVs bound and penetrated specifically into HER-2 expressing target cells. Similar cytotoxic effects measured by caspase-3/7 activity were found in CAR-T cells and their derived EVs. However, while the CAR-T cells induced massive apoptosis during the first 24 h, CAR-T EVs required 60 - 90 h. In summary, CAR-T EVs provide a novel potent immunotherapy approach that may be effective against solid tumors.

论文信息

作者
Aharon A、Horn G、Bar-Lev TH、Zagagi Yohay E、Waks T、Levin M、Deshet Unger N、Avivi I
第一作者单位
Hematology Research Laboratory for Extracellular Vesicles, Hematology Division, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.Israel
通讯作者单位
Immunology Laboratory, Research &amp; Development Department, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.Israel
文献类型
非美国政府资助研究
期刊
Human gene therapy2021 Oct
原文标识
PubMed 34494460 · DOI 10.1089/hum.2021.192